119 related articles for article (PubMed ID: 2268981)
1. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients.
Buur T; Lundberg M
Clin Nephrol; 1990 Nov; 34(5):230-5. PubMed ID: 2268981
[TBL] [Abstract][Full Text] [Related]
2. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
3. Influence of erythropoietin treatment on urea kinetic parameters in hemodialysis patients.
van Geelen JA; Nubé MJ; Zuurbier PA
Clin Nephrol; 1991 Apr; 35(4):165-70. PubMed ID: 1855319
[TBL] [Abstract][Full Text] [Related]
4. Impact of erythropoietin on the dialysis prescription.
Van Wyck DB
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
6. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal dialysis efficiency in CAPD patients in treatment with rHuEPO.
Vega N; Fernandez A; Hortal L; Macias M; Rodriguez JC; Plaza C; Perdomo M; Vega R; Palop L
Adv Perit Dial; 1992; 8():467-70. PubMed ID: 1361850
[TBL] [Abstract][Full Text] [Related]
8. Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin.
Bárány P; Pettersson E; Ahlberg M; Hultman E; Bergström J
Clin Nephrol; 1991 Jun; 35(6):270-9. PubMed ID: 1873941
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
[TBL] [Abstract][Full Text] [Related]
12. [Effect of recombinant human erythropoietin--rHu-EPO on the metabolism of children treated by long-term hemodialysis].
Pietrzyk JA; Smolnik T; Szymowska M; Dyras P; Lenik J
Przegl Lek; 1992; 49(1-2):55-60. PubMed ID: 1455008
[TBL] [Abstract][Full Text] [Related]
13. [Use of recombinant erythropoietin on secondary anemia in patients in the terminal phase of renal insufficiency on hemodialysis].
Gasparović V; Puretić Z; Vrhovac B; Gjurasin M; Puljević D
Acta Med Iugosl; 1990; 44(2):129-35. PubMed ID: 2353593
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
15. The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients.
Meierhenrich R; Jedicke H; Voigt A; Lange H
Clin Nephrol; 1996 Feb; 45(2):90-7. PubMed ID: 8846536
[TBL] [Abstract][Full Text] [Related]
16. How does rHuEPO effect D/P creatinine ratios?
Richmond D; Broyan P; Shea S; Reft C; Poseno M; Gimenez LF
Adv Perit Dial; 1992; 8():457-9. PubMed ID: 1361847
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
[TBL] [Abstract][Full Text] [Related]
18. Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients.
Kaupke CJ; Vaziri ND; Sampson JR; Atkins K
Int J Artif Organs; 1990 Apr; 13(4):218-22. PubMed ID: 2373550
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of anemia in chronic hemodialysis patients with recombinant human erythropoietin: long-term results in 15 patients].
Jacquot C; Berthelot JM; Chiappini-Judith D; Ferragu-Haguet M; Lefebvre A; Masselot JP; Moynot A; Frydman MO; Peterlongo F
Nephrologie; 1990; 11(1):11-6. PubMed ID: 2374641
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
